YMAB - Y-mAbs Therapeutics, Inc.
IEX Last Trade
13.595
0 0%
Share volume: 0
Last Updated: Fri 20 Dec 2024 09:18:12 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.46%
PREVIOUS CLOSE
CHG
CHG%
$13.60
-5.10
0.60%
Fundamental analysis
24%
Profitability
25%
Dept financing
5%
Liquidity
75%
Performance
15%
Performance
5 Days
-13.12%
1 Month
-20.46%
3 Months
-36.60%
6 Months
-31.57%
1 Year
21.94%
2 Year
73.58%
Key data
Stock price
$13.60
DAY RANGE
$8.50 - $13.60
52 WEEK RANGE
$6.85 - $20.90
52 WEEK CHANGE
$21.94
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Thomas Gad
Region: US
Website: ymabs.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ymabs.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Y-mAbs Therapeutics, Inc. focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment of cancer in the United States. The company is developing DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor. GD2-GD3 vaccine that is in Phase II clinical trial for the. treatment of Stage 4 high-risk neuroblastoma.
Recent news